Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT05616390
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 79 Years
Healthy Volunteers
Not accepted

Interventions

  • Sintilimab — DRUG
    200mg IV d1,Q3W
  • Bevacizumab — DRUG
    7.5mg/kg IV d1,Q3W
  • Liver Protective Support Therapy — COMBINATION_PRODUCT
    Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy

Study Details

To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma

Key Dates

First listed
Nov 15, 2022
Start date
Nov 9, 2022
Status verified
Nov 2022
Primary completion
Nov 30, 2023
Completion
Nov 30, 2025

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: experimental group
    Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy

Primary Outcome Measure

Adverse Events (AEs) [ Time Frame: Up to 3 years ]

Central Contacts

Related Studies